arXiv (All)
open access
Disease-level drug approval forecasting from trial-agnostic public data
Drug development is an expensive and lengthy process requiring developers to select drugs for human trials and diseases to target. Computational tools that can estimate before testing which drug-disease candidates are most likely to reach FDA approval could reduce development time and costs through
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Challenges and Opportunities in Statistical Analyses and Designs for Neuroscience Clinical Trials#1355822
- LongMedBench: Benchmarking Medical Agents for Long-Horizon Clinical Decision-Making#361513
- Understanding Lung Cancer Related Risk Factors and Their Impact#1046509
- From Fragmentation to Convergence Computational Biology, Research Clusters, and the Future of Pharmacology in the Age of the Computational Self#722956
- From Virtual Molecules to Clinical Trials: How AI Is Reshaping Preclinical Drug Discovery.#244368
Record · ID 1324614
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive